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Abstract
This article presents the revised consensus criteria for the diagnosis of frontotemporal dysfunction 
in amyotrophic lateral sclerosis (ALS) based on an international research workshop on 
frontotemporal dementia (FTD) and ALS held in London, Canada in June 2015. Since the 
publication of the Strong criteria, there have been considerable advances in the understanding of 
the neuropsychological profile of patients with ALS. Not only is the breadth and depth of 
neuropsychological findings broader than previously recognised – – including deficits in social 
cognition and language – but mixed deficits may also occur. Evidence now shows that the 
neuropsychological deficits in ALS are extremely heterogeneous, affecting over 50% of persons 
with ALS. When present, these deficits significantly and adversely impact patient survival. It is the 
recognition of this clinical heterogeneity in association with neuroimaging, genetic and 
neuropathological advances that has led to the current re-conceptualisation that 
neuropsychological deficits in ALS fall along a spectrum. These revised consensus criteria expand 
upon those of 2009 and embrace the concept of the frontotemporal spectrum disorder of ALS 
(ALS-FTSD).
Keywords
Amyotrophic lateral sclerosis; frontotemporal dementia; neuropsychology; cognition; behaviour; 
genetics
Introduction
While the core feature of amyotrophic lateral sclerosis (ALS) is a relentless loss of motor 
function leading to paralysis and ultimately death, the awareness that it can be associated 
with one or more features of frontotemporal dysfunction has gained increasing acceptance 
(1). This in part can be traced to the development of international criteria for the diagnosis of 
frontotemporal dysfunction in ALS in 2009 (Strong criteria) (2,3). These criteria, which 
incorporated clinical, electrophysiological, neuropsychological, genetic and 
neuropathological characteristics, recognised that ALS could exist as a pure motor syndrome 
but that it can coexist with a frontotemporal dementia (ALS-FTD) as defined by the Neary 
or Hodges criteria (4,5). The criteria further recognised that both behaviour and/or cognitive 
features, not sufficient to meet criteria for the diagnosis of dementia but sufficient to be 
detected and/or give rise to impairment, could exist (termed ALS behavioural impairment 
[ALSbi] and ALS cognitive impairment [ALSci], respectively). The criteria also 
acknowledged that a small population of patients could develop dementia not typical of FTD 
(ALS-Dementia).
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Since the introduction of the Strong criteria, our understanding of the breadth and impact of 
frontotemporal dysfunction has grown considerably. With this has come the realisation that 
the Strong criteria do not adequately recognise impairments in social cognition, language or 
memory, or the presence of neuropsychiatric symptoms and that these deficits are 
manifestations of the spectrum of deficits resulting from frontotemporal dysfunction. It is for 
this reason that we believe that the term frontotemporal spectrum disorder (ALS-FTSD) is 
most appropriate to characterise the breadth and severity of frontotemporal dysfunction that 
can be encountered in association with ALS. Moreover, the Strong criteria were not readily 
adapted to languages other than English and were insufficiently operationalised for easy use 
in everyday clinical practice or in clinical trials. Equally important, there have been 
significant advances in the genetics of ALS which have provided novel insights into the 
pathobiology of ALS-FTSD. Given this, a consensus conference was convened in the 
summer of 2015 to revisit the 2009 Strong criteria. A consensus development panel 
approach was utilised, which consisted of a group of content experts (manuscript authors) 
who identified key topic areas of relevance to developing these revised international 
guidelines. The expert panel then identified key international content experts who attended 
and/or presented at the international consensus conference in the summer of 2015. At the 
end of day 3 of the consensus conference, a round table discussion was held in which all 
attendees provided input into the key parameters of the revised criteria. Members of the 
consensus panel formulated the revised criteria, following which the criteria were provided 
to the conference attendees for commentary and/or revisions.
To that end, this article presents the revised Strong criteria. In doing so, we have addressed 
several key issues, including the recognition that any criteria must be sufficiently broad to be 
adequate for research purposes while at the same time be nimble enough to be of utility 
clinically. As such, beyond expanding the nature of neuropsychological and neuropsychiatric 
deficits that characterise ALS- FTSD, a key advance in this revision is the inclusion of three 
levels of complexity or depth of assessment: criteria which can be applied in everyday 
clinical use (Level I), those which can be utilised for prognostic stratification in clinical 
trials (Level II), and those which are considered as research intensive with the goal of better 
defining the nature and extent of FTSD in ALS (Level III) (Figure 1). The criteria are 
intentionally hierarchical. Level I incorporates tools that can be easily applied at the bedside 
and are of low statistical complexity, require the least amount of effort to implement, rely 
upon well-validated tools that have already been applied in the ALS population, and while 
not requiring neuropsychological support for implementation, would benefit from 
neuropsychological support for interpretation. Level III are the most advanced criteria and 
contain the core elements of the Level I testing but are of high statistical complexity, require 
a maximum amount of time and effort to complete, include research tools not yet validated 
in a broader ALS population, and would be considered research grade. Level II criteria are 
anticipated to be applicable to clinical trials where a moderate amount of effort could be 
expended. Level II criteria also would consist of a minimum dataset for inclusion in case 
publications. In contrast to Level I, Level II criteria require the engagement of either 
neuropsychologists or speech-language pathologists to evaluate the testing paradigms, to 
oversee or manage test administration and to interpret results.
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Participants at the consensus conference also agreed that the core features of the diagnostic 
algorithm, and most specifically the use of the diagnostic axis model, should remain while 
recognising that specific components would need either modification or expansion. Given 
this, the revised criteria continue to use the three primary ‘ diagnostic axes’ , including: Axis I 
– defining the motor neuron disease variant; Axis II – defining the cognitive and behavioural 
dysfunction; and, Axis III – additional non-motor disease manifestations. It was felt that the 
use of Axis IV which previously was included in order to define the presence of disease 
modifiers, did not contribute to the characterisation of the FTSD of ALS and thus it has been 
omitted in the revised criteria presented here.
Axis I. Defining the motor neuron disease variant
The phenotypic variability within ALS is significant and includes variability in age of onset, 
site of onset, the degree of upper verses lower motor involvement, the rate of disease 
progression and survival. Until such time as the basis for this heterogeneity is elucidated, it 
is helpful to recognise distinct clinical syndromes that may be characterised by the 
predominance of upper motor neuron degeneration (e.g. primary lateral sclerosis [PLS]), 
lower motor neuron neurodegeneration (e.g. progressive muscular atrophy [PMA]), or a 
combination of both UMN and LMN degeneration which typifies the most frequent 
phenotype, namely ALS; by the neuroanatomical region primarily affected (e.g. progressive 
bulbar palsy [PBP]); or by the absence (e.g. monomelic amyotrophy) or presence of left-
right symmetry (e.g. brachial amyotrophic diplegia, also known as flail arm, or leg 
amyotrophic diplegia).
Axis I diagnostic criteria—Since the publication of the original Strong criteria, there has 
been considerable debate with respect to the minimal criteria necessary to diagnose ALS, 
particularly with respect to the presence or absence of active denervation as diagnostic of 
LMN dysfunction. In the original Strong criteria, it was recommended that the El Escorial 
criteria (revised) be used for the diagnosis of ALS (6–8). In doing so, a multimodality 
approach toward identification of both UMN and LMN dysfunction using both clinical and 
electrodiagnostic studies was recommended, along with incorporation of genetic studies as 
appropriate. Neuroimaging studies were felt to be contributory when structural pathology 
was considered a diagnostic possibility but were otherwise relegated to being a research tool. 
The criteria further required the absence of any disease process that might account for the 
findings. In this context, the diagnosis of ALS required the presence of multisegmental LMN 
degeneration by either clinical or electrophysiological criteria combined with evidence of 
UMN dysfunction, with progression. Progressive upper or lower motor neuron dysfunction 
in a single segment, even if isolated, was considered sufficient for the diagnosis in the 
presence of a mutation in a known ALS causative gene.
There has since been considerable debate about the genesis of the delay in diagnosing ALS 
and whether such delays may hamper not only enrolment in therapeutic trials but the ability 
to impact on the earliest stages of the disease process. This has led to the introduction of 
alternative diagnostic algorithms, the intent of which are to include greater numbers of 
patients in clinical studies or trials who may have the potential of developing ALS while not 
yet fully manifesting the complete syndrome. The Awaji criteria, which emerged from a 
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consensus conference held in 2006, proposed two fundamental changes to the revised El 
Escorial (9). The first proposed change was to use both electromyography and clinical data 
simultaneously to determine the presence of LMN dysfunction. For example, atrophy in an 
ulnar innervated C8 muscle along with evidence of LMN pathology in the deltoid muscle, 
would be sufficient to declare the limb/region affected. The second proposed change was to 
consider fasciculation potentials as evidence of ongoing denervation, equivalent in 
importance to fibrillation potentials. While controversy has arisen over the notion that 
fasciculations represent ongoing denervation, there is greater agreement that unstable and 
complex fasciculations should be accorded greater significance. The Awaji criteria have been 
shown to have a higher sensitivity than the El Escorial criteria (revised) while maintaining 
the same specificity, with the diagnostic benefits being most apparent in the bulbar-onset and 
limb-onset patients (10–12). This increased sensitivity, however, is gained in large part by 
the combination of two El Escorial criteria (probable and laboratory supported probable) 
into a single category. The introduction of a ‘ possible’  diagnostic category to the Awaji 
criteria was of particular benefit in enhancing the early diagnosis of ALS and more 
specifically in the limb-onset subgroup (13).
More recently, the El Escorial criteria have been revisited in an effort to accommodate a 
postulated broader ALS phenotype (14). The revised iteration of the criteria proposed that 
the diagnosis of ALS would require, at minimum, progressive UMN and LMN deficits in at 
least one limb or region (previous possible ALS) or lower motor neuron deficits as defined 
by clinical examination (one region) and/or by EMG in two body regions (defined as bulbar, 
cervical, thoracic, lumbosacral). The EMG findings needed to include neurogenic potentials 
and fibrillation potentials and/or sharp waves. In this scheme, restricted phenotypes of ALS 
would now be considered as including progressive bulbar palsy, flail arm and flail leg 
syndrome, progressive muscular atrophy and primary lateral sclerosis. In the context of the 
flail arm and flail leg syndromes, as well as progressive muscular atrophy, the diagnosis of 
ALS could be rendered in the absence of evidence of UMN dysfunction. It was noted, 
however that the modifications of the El Escorial criteria as proposed by Ludolph et al. 
(2015) were as yet to be validated in longitudinal studies, and in particular the inclusion of 
pure LMN syndromes, as being equivalent to a diagnosis of ALS.
The role of biomarkers in the diagnosis and monitoring of progression in ALS continues to 
evolve, although to date, no markers specific to the presence of frontotemporal dysfunction 
have been validated. Thus, while there is evidence to suggest that a number of biomarkers 
within either cerebrospinal fluid or blood may prove to be of value in the diagnostic work-up 
of ALS patients with or without frontotemporal dysfunction, including high molecular 
weight neurofilament, phospho-tau (including measures of total tau), TDP-43, APOE ͧ2 and 
beta-amyloid are not yet ready to be included in Level I diagnostic work-up (15–21). 
Furthermore, while it is increasingly likely that proteomic profiling of CSF will enhance the 
sensitivity and specificity of biomarker utilisation in the diagnosis when used either 
independently or within a broader array of investigations including MR imaging (22,23), 
such testing should remain within the Level III work-up although a restricted number (e.g. 
pNFH, phospho-tau, TDP-43, APOE ͧ2) could be considered in Level II.
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Axis I genetic diagnosis—Since the publication of the original consensus criteria, 
significant advances have been made in our understanding of the genetic underpinnings of 
ALS; there are now over 17 Mendelian variants known to be associated with ALS that are 
considered causative (Table 1). In addition to these genes, an ever-expanding list of disease-
associated or disease-modifying genes are being discovered (Supplemental Table 1). While 
these discoveries are helping to advance our understanding of ALS, they also add substantial 
complexity in the clinical realm. While genetic characterisation of patients with ALS and 
ALS-FTSD is encouraged, it is critical to remember that the identification of a pathogenic 
variant in an ALS-causing gene does not imply the presence of disease. Moreover, while the 
term ‘ familial’  remains useful in describing the presence of a family history (i.e. at least two 
affected biological relatives) and as a surrogate for the likelihood of identifying a genetic 
cause of disease, it is important to remember that all genes implicated in familial forms of 
ALS also have been found to harbour mutations in a small subset of patients with apparently 
sporadic ALS. Moreover, by virtue of factors such as recessive inheritance, compound 
heterozygosity, de novo mutations, misdiagnosis, small sibship size, reduced penetrance, 
lack of family information, including paternity, etc., a family history may frequently be 
lacking in genetic forms of disease. The term ‘ familial’  therefore should not be used 
interchangeably with ‘ genetic’ (24). Conversely, given a lifetime risk of ALS, which 
approximates 1:350 for males and 1:400 for females, coincidental familial clustering is a 
realistic consideration among pedigrees with only two affected individuals which might 
otherwise be considered to be clinical examples of Mendelian inheritance (24).
Among ALS-disease causing genes, there are several that bear specific mention because 
their presence is disproportionately associated with frontotemporal dysfunction in ALS, 
sufficient to warrant genetic testing among those individuals with frontotemporal 
dysfunction regardless of the presence or absence of a family history. The prototypic gene 
amongst these is represented by the pathological hexanucleotide repeat (GGGGCC) 
expansions of C9orf72, which is the most common genetic modification affecting FALS 
(60–70%) as well as those afflicted with familial FTD (approximately 18% of cases). The 
presence of cognitive impairment in patients carrying a C9orf72 expansion is several-fold 
greater than those without (40–50% vs. 8–9%, respectively) (25). In rare instances in which 
ALS patients present with psychosis and marked lack of insight, there is also a higher 
likelihood of harbouring the pathological C9orf72 expansion (26).
Axis I recommendation
The classification of frontotemporal dysfunction in ALS should be hierarchical and begin 
with a description of the motor neuron disorder/syndrome.
While consensus has not yet been achieved with respect to the use of clinical syndromic 
terms, we perceive value in the use of terms such as progressive muscular atrophy, upper 
motor neuron predominant ALS and progressive bulbar palsy, for example, and recognise 
that the clinical syndrome may evolve over time. Such terminology is appropriately used in 
the clinic (Level I), in clinical trials (Level II) and as part of the broader research endeavour 
(Level III). Quite distinct from this syndromic nomenclature, however, is the use of 
diagnostic criteria such as the revised El Escorial and Awaji criteria for clinical trials (Level 
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II) and research purposes (Level III). It is recommended that patients diagnosed with ALS 
should fulfil either the El Escorial criteria (revised) or the Awaji criteria (revised).
Genetic testing is recommended when a family history is present (by which we mean that at 
least one other biological relative has been diagnosed with ALS or FTD), as the El Escorial 
criteria require only progressive upper or lower motor neuron dysfunction in the presence of 
a mutation in a gene known to cause ALS. We recommend that the term ‘ genetic ALS’  be 
used instead of ‘ familial ALS’ , especially when a genetic cause of disease is identified 
despite the absence of a family history. Appropriate genetic counselling should always be 
provided. For clinical trials (level II) and for research purposes (level III), a full genetic 
analysis (either a panel of genes established to cause ALS (Table 1)), or whole exome/
genome sequencing) is encouraged, and genetic counselling provided whenever genetic test 
results will be shared with the patient.
Axis II. Defining the neuropsychological deficits
The Strong criteria recognised the potential presence of FTD in ALS and for those patients 
not reaching threshold for a full FTD diagnosis, also provided a means of classifying the 
presence of cognitive or behavioural involvement – ALSci and ALSbi, respectively. Since 
the publication of the consensus criteria in 2009, however, developments in the field have 
necessitated the revision of these definitions. First, increasing evidence has accrued as to the 
heterogeneity of cognitive impairment in ALS. Thus, while previous emphasis had been 
placed on executive dysfunction, there is now evidence that language dysfunction may be as, 
if not more, common and can occur in patients without executive dysfunction (27,28). 
Deficits in social cognition also have been highlighted, although it is not entirely clear 
whether social cognition deficits are completely independent of executive dysfunction in 
ALS (29–36). Additionally, while the original ALSci and ALSbi classifications have been 
borne out by cluster analysis, it has been suggested that other cognitively-impaired patients 
cannot be classified according to the original criteria (36). There is also some controversy (to 
be considered below) about the role of memory dysfunction in the classification of cognitive 
impairment in people with ALS. Secondly, revised consensus criteria for the diagnosis of 
behavioural variant FTD (bvFTD) highlight the need for revising the current consensus 
criteria (37).
Our aim, therefore, is to revise the previous classifications of cognitive and behavioural 
involvement in ALS to take into account the extended evidence base of potential deficits that 
may need to be considered in arriving at a classification of impairment and to account for the 
increased knowledge and heterogeneity of impairment profiles. First, we examine the 
developments below in specific cognitive domains that have given rise to this need for 
revision; then we consider revisions to the classification of behavioural and neuropsychiatric 
symptoms and provide recommendations regarding testing paradigms (Supplemental Table 
2).
Neuropsychological domains
a) Executive dysfunction and Social Cognition: Executive dysfunction is characteristic 
of the profile of cognitive deficits in ALS (38), a finding that has been confirmed through 
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population based studies (39) and meta-analyses (40). The signature executive functions 
deficit is demonstrated through assessment of verbal fluency (41–44). This is a commonly 
used clinical instrument, involving the generation of lists of words beginning with a 
specified letter (letter fluency) or semantic category (e.g. animal fluency), the former being 
the more widely recognised marker of impairment in ALS. Letter fluency involves the 
interaction of a number of cognitive processes, specifically executive processes of initiation, 
strategy formation, set-shifting, sustained attention and inhibition, but in addition language 
functions involved in word retrieval. It has been shown that poor letter fluency in ALS is 
related to executive dysfunction (41). Deficits on letter fluency tasks occur early in the 
course of the disease (45), correlate with ocular movement abnormalities (46), and are more 
prominent in but not restricted to patients with pseudobulbar palsy (42). Based on limited 
published literature, impaired verbal fluency does not appear to be a feature of SOD1-ALS 
(47).
Verbal fluency deficits in ALS also have been shown to be a marker of frontal lobe 
dysfunction, in particular the dorsolateral prefrontal cortex and inferior frontal gyrus, as 
demonstrated with functional and structural neuroimaging (48–51). Performance in verbal 
fluency can be affected by motor disability with difficulties in writing or in speaking, which 
magnify deficits. This has necessitated the development of the Verbal Fluency Index that 
controls for physical motor impairments by incorporating a timed condition in which the 
person either reads or copies previously generated words and from which an estimate of the 
average time taken to think of each word is calculated. Using the Verbal Fluency Index, 
deficits have been repeatedly demonstrated that are independent of motor disability (41).
Executive dysfunction in ALS has been revealed across a range of tests including readily 
available clinical measures and experimental procedures. Deficits have been reliably shown 
on standard assessments measuring attention monitoring and switching, rule deduction, and 
cognitive flexibility, such as the Trail Making Test or the Wisconsin Card Sorting Test 
(52,53). A recent meta-analysis of studies using the latter revealed that patients with ALS 
made more errors (continuing to choose the previously correct rule) and took longer to learn 
new rules (54). Similar impairments have been shown on other card sorting concept 
formation tasks such as from the Delis-Kaplan Executive Function System Sorting Test 
(34,55). Furthermore, deficits have been revealed on tests highly reliant on manipulating 
concepts in working memory such as reverse digit span or the N-Back task and most 
recently on tests of divided attention in which two tasks are undertaken concurrently, such as 
visual processing speed task and digit recall (51).
Performance on standard neuropsychological tests of executive function are mostly mediated 
by functions of the dorsolateral prefrontal cortex, but studies have also revealed deficits 
using experimental measures more dependent on orbitomedial prefrontal functions. ALS 
patients have shown abnormal risk taking on the Iowa Gambling Task (29). Deficits have 
been shown using two more ecologically valid measures of executive functions where 
patients demonstrate difficulties in reasoning, coordinating rules and mental heuristics – the 
Medication Scheduling Task (56) and the Holiday Apartment Task (57).
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Social cognition has recently become a focus of investigation in ALS, having been a notable 
feature of the FTD profile for some time. A recently updated meta-analysis noted the new 
addition of social cognition deficits as integral to the cognitive profile in ALS (40). 
Nevertheless, there remains some debate as to the source of the deficits in social cognition 
with some studies showing an independence of executive dysfunction and others not (34,57). 
Patients with ALS show deficits across a range of social cognitive processes including 
altered emotional processing and reduced capacity to recognise emotional (particularly 
negative) facial expressions although this is more likely in those with ALS-FTD (29,58–60). 
ALS patients also have difficulty on tests specific to Theory of Mind, in which the thoughts 
or beliefs of another are inferred. One-third of patients have been shown to be impaired at 
detecting a faux pas (57) and such difficulties have been related to specific problems with 
understanding social situations (30).
A fundamental process in social cognition is the interpretation of the direction of eye gaze as 
assessed through the Judgement of Preference Task (29). The finding of a deficit on this task 
was extended to reveal impaired affective and to a lesser extent cognitive Theory of Mind 
(35).
In patients meeting criteria for ALS-FTD, executive/social cognition deficits are a virtually 
ubiquitous feature and cover the range of difficulties described above.
b) Language dysfunction: The last two decades have seen a rising interest in defining the 
prevalence and the nature of the language impairment in ALS (27,39,61–64). The extent to 
which impairments in word retrieval, sentence processing, spoken language, and pragmatic 
language are ‘ pure’  language deficits versus downstream manifestations of other disrupted 
cognitive domains (e.g. executive function) continues to be debated. Not all patients with 
ALSci present with obvious language impairments (65). Moreover, language deficits in 
ALSci can be challenging to disentangle from motor speech deficits and also from ALS-
FTD, which can present similarly to semantic and non-fluent variants of primary progressive 
aphasia. Notwithstanding these diagnostic challenges, an estimated 35-40% of individuals 
with ALS but no dementia may demonstrate language impairments (27). These language 
impairments are dissociable from motor and executive function impairments (28,62,66–69), 
raising the possibility that impairments in language may both contribute to the profile of 
ALS and also occur as part of a mixed cognitive profile that includes executive function 
impairments or social cognition impairments (27,36).
In ALS, word retrieval for nouns and object knowledge are often reported as mildly 
impaired compared with controls (28,49,62,70,71). In contrast to nouns, verb naming and 
action verb processing deficits are a more consistent finding in ALS (27,28,62,69,71–73). 
Verb deficits in ALS are often associated with atrophy in the dorsolateral prefrontal cortex 
and motor cortices (69,71,72). As such, they may be an important marker of cognitive 
impairment in ALS. While the theoretical underpinning of the object-action (i.e. noun-action 
verb) dissociation observed in ALSci remains unclear (73), these findings suggest that the 
assessment of word retrieval impairments may benefit from including tests that measure the 
retrieval and comprehension of both nouns and action verbs.
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Sentence processing difficulties also have emerged as a prominent feature in the language 
profile of ALS (27,28,72,74,75). Recent work suggests that syntax and sentence processing 
deficits in ALS probably exist on a spectrum with modest impairments emerging in ALS 
that progress in severity for patients with ALS-FTD (75). While more research is needed, 
deficits in syntax processing have been dissociated from both executive function and motor 
speech impairments (28), suggesting that syntax processing impairments may contribute 
uniquely to the language profile of ALS.
There is emerging evidence that, in addition to sentence processing deficits, individuals with 
ALS also produce sentences with a greater number of grammar and morphology errors 
compared to healthy adults (28,62,66). Grammatical errors reported from studies of spoken 
language in ALS include incomplete utterances (28,66,68), missing determiners (66), and 
verb phrase errors (66). Productivity deficits also characterise the spoken language of 
individuals with ALS including reduced utterance length and lower total word output, 
features that are probably related to the motor speech and respiratory challenges in ALS 
(28,67,68). Beyond grammar and productivity impairments, other linguistic and pragmatic 
aspects of spoken language are affected in ALS including informativeness (e.g. fewer 
content or information words in proportion to the total words produced) (68,76); semantic 
and verbal paraphasias (28,68); poor narrative coherence and cohesion (66); and impaired 
topic management (76). While it remains an evolving area of research, investigators have 
reported impaired pragmatic language in ALS including figurative and non-literal language 
processing, findings that are often attributed to frontal lobe dysfunction (76).
Collectively, the research over the last decade underscores the importance of considering 
language impairments in the profile of ALSci. Although analysis of spoken language tasks 
may be more challenging for typical clinical environments, due to their more labour 
intensive analyses, clinicians and researchers can glean much about the profile of language 
impairments in ALS using a number of available standardised instruments (Supplemental 
Table 2).
The relationship between language impairment and ALS-FTD also is incompletely 
understood. Progressive non-fluent aphasia (PNFA) and semantic dementia (SD) are clinical 
forms of frontotemporal lobar degeneration incorporated within previous diagnostic criteria 
(5). Both PNFA and SD have been reported in association with ALS (77–80). On the other 
hand, specific language problems, such as in syntactic comprehension, are reported to be 
common in patients meeting behavioural criteria for ALS-FTD (75). Criteria for ALS-FTD 
need to recognise that language problems play a contributory role.
c) Memory: Memory deficits in ALS have been studied extensively. However, in the 
current recommendations, isolated memory impairment does not meet the criteria for a 
diagnosis of ALSci. The exclusion of memory dysfunction from the current criteria relates 
in part to the lack of consensus about the characterisation of memory deficits in ALS. Study 
results are wide ranging and have identified impairments in encoding (81–83), immediate or 
delayed recall (39,78,81,83–85), recognition (86), or the involvement of a combination of 
memory processes. Other studies suggest intact recognition memory (39,83,87).
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An updated meta-analysis in ALS showed a small effect size for delayed verbal memory as 
well as executive dysfunction, with larger effect sizes for other domains (fluency, language 
and social cognition) (40). Although delayed verbal memory recall was associated with a 
greater effect size than visual memory (40), visual memory deficits have been detected (78). 
Memory deficits are detected in ALS patients without dementia that correlate with grey 
matter hippocampal volumes (85) and memory scores may differ significantly from controls 
even in cognitively-normal ALS patients (78). ALS patients with baseline cognitive 
impairment demonstrate decline in verbal delayed recall when studied longitudinally (84).
Of importance for further understanding why isolated memory involvement should not be 
used to classify ALSci, memory impairment in ALS rarely occurs in isolation (4%), which is 
a comparable rate to that seen in controls (39). The association between executive 
dysfunction and memory impairment in ALS is asserted repeatedly (78,81– 83,86,87). 
Variables such as selective attention and mental control explain substantial variance in 
memory scores. Interestingly, memory deficits are the least common comorbidity in ALSci 
patients who present with executive dysfunction (39).
With respect to the broader implications of detecting memory impairment in people with 
ALS, a population based study detected Alzheimer’ s disease (AD) in 1.9% of ALS patients, 
compared to 13.8% of the sample who had FTD (39). In a study of 279 ALS patients (78), 
<2% met diagnostic criteria for AD, a frequency lower than the national rate of AD in 4% of 
the US population of adults below age 64 years (88). In the ALS study, similarities in 
cognitive performance across cognitive diagnostic subgroups suggested different levels of 
severity within the same progressive disease subsumed by executive dysfunction. The results 
did not support the presence of discrete subtypes (i.e. an amnestic subtype). Qualitative 
differences in memory distinguish ALS patients from patients with AD (83) and those with 
the AD prodrome of mild cognitive impairment-amnestic type (86).
Although isolated memory impairment does not qualify for the diagnosis of ALSci, memory 
impairment may nonetheless be problematic for patients, particularly for those in the older 
age segment of its distribution. To better understand its nature, assessment of memory in 
ALS should also analyse domains of attention, language, and executive functioning and age-
related changes in the speed of processing. Ideally, research studies investigating memory 
should analyse multiple variables such as encoding, storage, recall, processing speed, and 
recognition rather than summarising a single memory composite score, which may obscure 
the understanding of the specific memory deficit (86). As with any clinical evaluation, 
memory assessment in ALS should consider alternative conditions that result in memory 
impairment and factors such as respiratory muscle weakness that may give rise to nocturnal 
hypoxaemia. Supplemental Table 2 provides a list of screening measures and comprehensive 
memory tests that can be used in the ALS population.
d) Behavioural changes and neuropsychiatric symptoms: Apathy is the most frequently 
identified behaviour symptom in ALS, detected in up to 70% of patients (89–95). There is 
not a clear link to specific ALS phenotypes, apathy being pervasive, and severe apathy being 
linked to poorer prognosis in ALS (96). ALS patients may present with other types of 
behaviour change including disinhibition, loss of sympathy/egocentric behaviour, 
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perseverative and stereotyped behaviour and a change in dietary habits, although not as 
commonly as apathy (91,97,98).
When assessing behavioural change in ALS, it is important to consider potential confounds 
of respiratory insufficiency, physical disability and psychological reactions to the disease 
including mood. Reports from family members or friends are essential, especially in light of 
the patient’ s lack of insight. Baseline/premorbid psychological and behavioural status must 
be determined in order to assess whether behavioural abnormalities are 1) new; 2) associated 
with the time of onset of ALS (recognising as stated earlier that a proportion of FTD patients 
will develop either clinical or electrophysiological features consistent with either ALS or a 
motor neuron disease); and 3) disabling or causing clear impairment. Individuals assessing 
these patients also need to be knowledgeable about pseudobulbar affect, which may be 
misinterpreted by some as behavioural disinhibition, inappropriateness, or depression. In 
turn, the distinction between apathy and depression is of great relevance not only for the 
diagnosis of ALSbi, but also for the clinical management of depression (when present) and 
provision of family support.
It is important to acknowledge that these behavioural symptoms often coexist with deficits in 
cognitive domains (see ALScbi; see Table 2). In addition, ALSbi and ALSci can coexist with 
different levels of severity (99–101). In some patients the combination of behavioural and 
cognitive changes are sufficient to meet criteria for ALS-FTD.
Behavioural changes and neuropsychiatric symptoms have been merged into one category to 
align bvFTD current criteria with current research findings, as indicated in Supplementary 
Table 3.
Axis II recommendations
Since the introduction of the Strong criteria, several reliable screening and assessment tools 
have been developed with which to describe the cognitive, behavioural and language profile 
of an ALS patient. These tools have been validated and are readily applied in the clinical 
setting, allowing for brief screening or testing that can be introduced efficiently into the 
clinic as an indicator of those ALS patients who may require more intensive study 
(Supplemental Table 2). As such, therefore, it is recommended that each patient receive a 
screening assessment as a component of a Level I evaluation and, if impaired, that further 
testing is warranted.
Screening and brief assessments.—Screening assessments are designed first to 
identify those individuals who have evidence of frontotemporal dysfunction, and secondly, 
to provide some degree of differentiation as to the type of dysfunction. Where ALS 
screening tests are administered, ALSci is identified on the basis of the published cut-off 
scores. The advantage of using ALS screening tests such as the ECAS and ALS Cognitive 
Behavioural Screen (ALS-CBS) is that the identification of ALSci may otherwise be based 
on individual tests of variable levels of complexity, thereby contributing to the heterogeneity 
of identified samples. While both of these tools allow for the identification of ALSci, where 
further description of the extent of frontotemporal dysfunction is desirable, patients can then 
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be assessed in greater detail using the tests proposed in Supplemental Table 2. To that end, it 
is recommended that either the ECAS or the ALS-CBS be administered to all patients.
The Edinburgh Cognitive and Behavioural ALS Screen (ECAS).—ECAS is a 
multidomain brief assessment developed for use within the clinic or home visits by non-
neuropsychology health professionals (102,103). It assesses a range of functions typically 
affected in ALS (ALS-Specific: Fluency, Executive Functions, Language Functions) 
including newly recognised deficits in language and social cognition. In addition, it assesses 
functions that are not typically affected in ALS but are common in disorders of older adults 
(ALS Non-specific: Memory, Visuospatial Functions). The ECAS also includes a separate 
semi-structured behaviour interview that should be undertaken with an informant/caregiver 
separately from the patient and is based on the five key behavioural domains for diagnosing 
FTD (see above) using the most recent diagnostic criteria (37) and can therefore be used to 
aid in the diagnosis of behavioural variant FTD.
The cognitive tests were specifically designed to allow for verbal and motor disability, 
incorporating the Verbal Fluency Index, and the whole assessment can be undertaken in 
either spoken or written format. The screen has been validated against extensive 
neuropsychological assessment and shows good sensitivity (85%) and specificity (85%) to 
cognitive impairment in ALS patients without dementia (104). In the English versions, 
abnormality cut-off scores were 105/136 for ECAS-Total Score and 77/100 for ALS-
Specific Score. A five-point borderline range (105–110) and (77–82) produced optimal 
values maximising sensitivity without a significant reduction of specificity and is 
recommended particularly for highly educated patients. Additionally, the ECAS has been 
validated in German (104), Italian (105) and Chinese (106) and shows convergent validity 
with other general cognitive screening tools, including the Frontal Assessment Battery and 
the Montreal Cognitive Assessment. The ECAS has been translated into a number of other 
languages and adapted for a North American population.
ALS Cognitive Behavioural Screen (ALS-CBS).—The ALS-CBS (107) was 
developed as a quick, practical tool to aid in the identification of ALSci, ALSbi, and FTD in 
the clinical setting. It includes a cognitive section and a caregiver questionnaire. It has high 
concurrent validity with other ALS-specific measures (44) and has excellent accuracy (107). 
High inter-rater reliability and ease of use was demonstrated in a large, multicentre study 
(44). The ALS CBS has been translated into six languages and it has been validated in 
Portuguese (108) and Spanish (109). It is freely available and non-copyrighted, as is ECAS.
The ALS-CBS was developed to minimise motor or speech production involvement so 
patients can be tested during later stages of the disease. Responses can be provided verbally 
or in writing and can be generated with speech output devices or communicated with eye 
movements or mouthing. It can be administered by any clinical staff member, and requires 
approximately 5 min to complete. The cognitive section measures attention, concentration, 
working memory, fluency and tracking. Only the verbal fluency item is timed. Certain 
cognitive items were chosen based on research that identified an association between errors 
made on specific items and the severity of cognitive impairment in ALS. Scoring combines 
correct responses minus deductions for errors, with a total possible score of 20. Lower 
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scores reflect greater impairment. Optimal cut-off scores were determined in the initial 
validation study (107). A cut-off of ≤10 for the cognitive section achieved 100% accuracy 
for identifying FTD in the study of ALS patients diagnosed with dementia based on a 
comprehensive neuropsychological battery. Scores at or below this cut-off raise strong 
suspicion of FTD and should prompt further assessment to confirm the diagnosis. A cut-off 
score of ≤16 suggests any cognitive impairment (either ALSci or ALS-FTD), and a score of 
≥17 is recommended to exclude cognitive impairment.
The behavioural section comprises a 15-item Likert scale questionnaire completed by an 
inform- ant and assesses change since disease onset. Behavioural domains were selected to 
assess a variety of abnormalities known to occur in ALS and FTD, including alterations in 
empathy, personality, judgment, language, and insight. Total scores range from 0 to 45; 
lower scores indicate more pathology. For the behavioural section, a cut-off of ≤32 achieved 
86% accuracy for correctly classifying ALS patients with FTD and a score of ≤36 best 
detects any behavioural impairment (ALSbi or ALS-FTD). Scores above ≥37 are suggestive 
of normal behaviour.
Domain-specific recommendations
ALS with cognitive impairment (ALSci)—A diagnosis of ALSci depends on evidence 
of either executive dysfunction (including social cognition) or language dysfunction or a 
combination of the two.
Executive impairment is defined as:
1. Impaired verbal fluency (letter). Verbal fluency deficits must control for motor 
and/or speech impairments (41) to be valid.
OR
2. Impairment on two other non-overlapping measures (see below) of executive 
functions (which may include social cognition).
Language impairment is defined as:
1. Impairment on two non-overlapping tests (which could include pragmatic 
function).
As the investigator or clinician elects to move to a higher level of complexity or depth of 
assessment (i.e. Level II and III; see Supplemental Table 2), impairment on individual 
measures (not screening tests) is defined as a score falling at or below the 5th percentile, 
compared to age- and education- matched norms. Deficits should not be better accounted for 
by the person’ s premorbid intellectual level or native language, although this comparison 
might be best interpreted within a specialist clinical neuropsychological assessment. At both 
Level II and III studies, carefully matched control groups will help inform detection of 
impairment. In addition, at both Level II and III studies, a neuropsychologist and a speech 
language pathologist are considered mandatory to assist with the administration and 
interpretation of the test results. Where individual assessment tools (rather than a screening 
or brief assessment battery) are used, the identification deficits on non-overlapping measures 
should be guided by the following considerations: measures of impairment should not be 
Strong et al. Page 14
Amyotroph Lateral Scler Frontotemporal Degener. Author manuscript; available in PMC 2020 August 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
derived from the same test; and, tests on which impairment is identified should not involve a 
similar format (e.g. investigators would not include impairment on two tests of attention-
inhibition, or concept formation or two tests of naming, see Supplemental Table 2).
Although the above criteria will potentially exclude people who have a selective breakdown 
on only one executive function (other than verbal fluency) or language test, we are 
concerned not to over-diagnose ALSci.
Clinical assessments and research studies should rule out confounding factors that may or 
not may be associated with ALS. A comprehensive assessment should rule out other 
cognitive presentations. Assessment procedures should control for bulbar speech production 
impairments (dysarthria) and motor deficits wherever possible so that deficits are not 
primarily identified on the basis of timed tests. Where serial measurements are available, a 
decline from baseline of at least 1.5 sd on a measure might also be considered to indicate 
(new) impairment, although caution also has to be taken to evaluate the likely effect of 
repeated testing on performance where no new deficits are elicited, especially where parallel 
versions of tests are not available. For this reason, control groups are vitally important in 
clinical trials and longitudinal research studies.
ALS with behavioural impairment (ALSbi)—While both the ECAS and ALS-CBS 
contain behavioural measures, the delineation of the behavioural characteristics can be 
further gained through either the Motor Neuron Disease Behaviour Scale (MiND-B) (110), 
the Amyotrophic Lateral Sclerosis-Frontotemporal Dementia-Questionnaire (ALSFTD-Q) 
(111) or the Frontal Behavioural Inventory – ALS Version (FBI-ALS) (44,112). In each, the 
diagnosis of ALSbi is dependent on evidence from informant interviews and clinical 
observation of alterations in behaviour that cannot be accounted for by disease-related 
limitations, psychological reaction to the ALS diagnosis, a premorbid personality disorder, 
the presence of a comorbid psychiatric disorder (e.g. anxiety or depression) or pseudobulbar 
affect.
MiND-B is a brief assessment (nine items) completed by a proxy informant who knows well 
the person diagnosed by ALS. It includes three domains: disinhibition, stereotypical 
behaviour and apathy. It is derived from the Cambridge Behavioural Inventory Revised, 
which was originally developed to be sensitive for FTD. The MiND-B was validated in ALS 
with a data driven approach. Two cut-offs to distinguish ALS from ALS plus (defined in 
MiND-B as patients with either ALSci or ALSbi) or FTD are available: 35/36: 90% 
sensitivity and 50% specificity and 33/36: 81% sensitivity and 75% specificity.
The ALSFTD-Q is a caregiver questionnaire that was developed to measure abnormal 
behavior change in ALS and avoid response bias due to physical disability. The 25 items 
were selected on the basis of a systematic review of the ALS literature and cover apathy, 
irritability, disinhibition, emotional lability and altered food preference. It shows good 
construct validity against other measures of behaviour change (Frontal Systems Behaviour 
Scale and Frontal Behaviour Inventory) and discriminates well ALS-FTD from ALS and 
controls. The cut-offs for this scale provide distinctions between mild behavioural symptoms 
(ALSbi) and more severe symptoms, although not for a particular behaviour.
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Loss of insight must be established by comparing patients’  and informants’  accounts of 
behavioural change and this may require clinical opinion. One means of operationalising 
insight is to analyse standardised score discrepancies between patient self-reports and 
caregiver reports of patient behaviour. One study determined that ALS-FTD patients report 
significantly less behavioural change over time compared to their caregivers, and report 
fewer behavioural abnormalities overall (113). The extent of patient-caregiver discrepancy 
was not documented in ALS patients without dementia.
On the basis of information gained from a knowledgeable informant, a diagnosis of ALSbi is 
defined by:
1. The identification of apathy with or without other behaviour change.
OR
2. The presence of two or more of the following behavioural symptoms: a) 
disinhibition, b) loss of sympathy and empathy, c) perseverative, stereotyped or 
compulsive behaviour, d) hyperorality/dietary change, e) loss of insight (see 
above), f) psychotic symptoms (e.g. somatic delusions, hallucinations, irrational 
beliefs). The behavioural features a–d, together with apathy, are drawn from 
current criteria for behavioural variant FTD (37).
The ECAS behaviour screen provides a checklist of symptoms from the diagnostic criteria 
that are marked as present or not. Other ALS-specific behavioural screens like the ALS-CBS 
and MiND-B provide published cut-off scores which are used to define ALSbi.
ALS with combined cognitive and behavioural impairment (ALS-cbi)—This new 
classification captures patients who fulfil criteria for both ALSci and ALSbi.
ALS with frontotemporal dementia (ALS-FTD)—A diagnosis of ALS-FTD is made 
when patients with ALS also show behavioural/cognitive changes in keeping with FTD.
A diagnosis of ALS-FTD is defined by:
1. Evidence of progressive deterioration of behaviour and/or cognition by 
observation or history
AND
2. The presence of at least three of the behavioural/cognitive symptoms outlined by 
Rascovsky et al. (37).
OR
3. The presence of at least two of those behavioural/cognitive symptoms, together 
with loss of insight and/or psychotic symptoms
OR
4. The presence of language impairment meeting criteria for semantic dementia/
semantic variant PPA or non-fluent variant PPA, as defined by Neary et al. (5) or 
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Gorno-Tempini et al. (114). This may coexist with behavioural/cognitive 
symptoms as outlined above.
Neuroimaging studies in the diagnosis of a frontotemporal spectrum disorder 
in ALS—Neuroimaging continues to provide unique in vivo pathological insights into the 
expanding clinical and molecular syndrome of ALS (115). While frontotemporal cerebral 
atrophy may be noted during CT or MRI performed as part of the routine clinical work-up of 
ALS patients, both are insensitive and in the clinical setting a subjective assessment must 
take into account normal age-related atrophy. SPECT, long-recognised to be capable of 
demonstrating reduced frontal uptake in cases of ALS associated with dementia (116), also 
lacks essential sensitivity for ALS cases with less marked cognitive or behavioural 
impairment. Automated assessment tools for detecting more subtle grey matter volume 
changes on high-resolution T1-weighted MRI (voxel-based morphometry), or 
frontotemporal white matter tract projections (diffusion tensor imaging), are not yet 
applicable to the individual patient. However, these more advanced structural MRI 
sequences continue to advance toward this ultimate aim (117), perhaps through combination 
with functional MRI connectivity measures (118).
More marked patterns of basal ganglia and cerebellar structural MRI change have been 
noted in ALS patients carrying pathological hexanucleotide expansions in C9orf72 
compared to apparently sporadic ALS cases (119,120). Furthermore, widespread structural 
MRI changes have been reported in studies involving pre-symptomatic C9orf72 mutation 
carriers (121,122), offering the potential to study the evolution of broader cerebral pathology 
in ALS at a much earlier stage.
Positron emission tomography (PET) imaging continues to provide substantial knowledge 
regarding the anatomic and cellular topography of neuronal dysfunction in ALS and, 
increasingly, markers of non-neuronal involvement as critical mediators of the disease 
process. Advances in neuroimaging and the attendant increase in our understanding of the 
neural networks or connectome are beginning to provide greater clarity as to the nature of 
FTSD, and in particular the concept of FTSD as a disconnection syndrome with individual 
clinical phenotypes predicated on the nature of the neural network damage. Providing crisp 
clinical correlates to such neuroimaging advances underlies a significant proportion of the 
impetus to revising the criteria.
Axis III. Additional non-motor disease manifestations
As with the 2009 Strong criteria (2), it is recommended that note be made of the presence or 
absence of non-motor manifestations, including extrapyramidal signs (bradykinesia, rigidity, 
tremor), cerebellar degeneration, autonomic dysfunction, sensory impairment 
disproportionate to age or ocular movement abnormalities.
Axis III recommendation
Members of the Consensus Committee made no changes to this recommendation. As such, it 
is recommended that observations should be made of specific non-motor manifestations that 
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are distinct from the neuropsychiatric and neuropsychological manifestations of 
frontotemporal dysfunction.
Axis IV. Presence of disease modifiers
In reviewing this recommendation, members recognised that the majority of modifiers of the 
neuropsychological features of ALS would be captured within Axis I studies of the 
molecular genetics or within the specific tests of neuropsychology. All studies will contain 
the key variables of site of disease onset, gender and age. Hence, the view of the members of 
the consensus conference was that Axis IV was no longer required within the diagnostic 
algorithm of the frontotemporal spectrum disorders of ALS.
Axis IV recommendation
As noted above, members recommend that Axis IV is no longer required and be supplanted 
by information gained through the assessment of Axis I and II.
Neuropathology recommendations—The fundamental recommendations of the Strong 
criteria with respect to neuropathological diagnosis of ALS-FTSD remain unchanged. 
However, in keeping with the consideration of levels of complexity, it is recognised that not 
all cases will be examined as extensively as was proposed, although this remains the goal. 
As such, a complete neuropathological examination should be considered to be integral to 
the diagnosis, including examination of the brain and complete spinal cord given the high 
degree of regional variability of the disease and recent work suggesting a focal onset 
followed by spread (123–125). Spinal cord sections should continue to include cervical, 
thoracic and lumbar regions. Due to the pathognomonic involvement by p62 and dipeptide 
repeat (DPR) pathology in C9FTD/ALS, the cerebellum must be included in the analysis 
(126,127). In all cases, the degree of involvement of both the UMN and LMN should be 
ascertained and, for the former, when not clearly evident on routine haematoxylin/eosin 
staining, identified using immunohistochemical evidence for a microglial 
neuroinflammatory response (e.g. HLA-DR3, CD68 or Iba1) and astrogliosis (GFAP), and 
special stain (e.g. Luxol-fast blue/Nissl) for secondary myelin loss. With the increasing 
recognition that neuronal cytoplasmic and nuclear inclusions within degenerating motor 
neurons in ALS can be composed of a broad range of cytoskeletal proteins and RNA binding 
proteins, often with multiple proteins depositing within the same degenerating motor neuron 
(128), there is now an extensive array of antibodies with which to confirm the presence of 
ALS. Most commonly, however, immunostaining with antibodies directed towards protein 
ubiquitination (ubiquitin, p62), TDP-43 and FUS and demonstrating neuronal or glial 
inclusions would suffice for the diagnosis of LMN involvement in ALS. When full autopsy 
is possible, peripheral nerves and muscles should be part of the neuropathological work-up. 
Sampling frozen tissue for future biochemical and genetic analysis also is recommended.
The neuropathological correlate of FTD is frontotemporal lobar degeneration (FTLD). There 
are three major FTLD types depending on the hallmark pathological protein: FTLD-tau, 
FTLD-TDP and FTLD-FUS. A small minority of FTD cases are not expressing any of these 
proteins; those reacting with markers of the ubiquitin-proteasome system (UPS) represent 
FTLD-UPS whereas the rare, completely immunonegative cases fall into the group of 
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FTLD-NOS (not otherwise specified). The large majority of cases of ALS with 
frontotemporal dysfunction belong to the FTLD-TDP type and exhibit TDP-43 
immunoreactive inclusions within a range of neocortical and subcortical structures (the 
remaining cases are FTLD-FUS). They are predominantly in neurons in forms of neuronal 
cytoplasmic inclusions (NCIs), dystrophic neurites (DNs) and neuronal intranuclear 
inclusions (NIIs). The harmonised classification system for FTLD-TDP recognises four 
subtypes (A, B, C and D) depending on the morphological forms and their frequency, 
characteristic neuroanatomical localisation and presence or absence of other features like 
hippocampal sclerosis (129). There is good correlation with clinical phenotypes and genetic 
alterations (for example, the most frequent subtype A often presents with bvFTD and FTD-
ALS, with 50% of cases harbouring GRN mutation or c9orf72 expansion).
For neuropathological analysis, due to regional specificity, representative sections should 
include (among others) the anterior cingulate gyrus, pre-central gyrus, superior frontal 
gyrus, superior temporal gyrus, amygdala, entorhinal cortex, hippocampus, basal ganglia 
and cerebellum. Immunostaining should include antibodies against TDP-43, FUS, p62, tau 
(e.g. AT8, pThr175) (130,131), ͣ-synuclein and in specific disease subtypes against 
neurofilament (in neuronal intermediate filament inclusion disease - NIFID), SOD-1, and 
various dipeptide repeats (DPRs) (in C9FTD/ ALS) (132). Assessment of the presence of 
amyloid beta (Aͤ) pathology (e.g. amyloid plaques, cerebral amyloid angiopathy) with or 
without Alzheimer’ s disease type tau pathology also is mandatory. As discussed in the 
original Strong criteria, neuropathological studies should describe, by region, the extent of 
neuropathological changes, including the presence or absence of superficial linear 
spongiosis, the degree of neuronal loss, the presence or absence of hippocampal sclerosis 
(including subtle focal loss of CA1 neurons), and the nature of inclusions present (including 
dystrophic neurites, neuronal cytoplasmic inclusions, and neuronal intranuclear inclusions). 
The presence or absence of glial pathology, whether astrocytic or oligodendroglial, should 
be delineated. A stepwise approach is recommended for neuropathological work-up with 
special stains and immunohistochemistry of the relevant brain and spinal cord regions (132). 
A diagnostic algorithm has been proposed recently for neuropathological diagnosis of ALS, 
FTD and overlapping syndromes (132). More details about the principles and practice of 
neuropathological analysis and key morphological features are described in reference 
textbooks (132–134).
Since the publication of the original Strong criteria, the concept of staging of the 
frontotemporal degeneration of the neocortical and subcortical involvement in ALS has 
become increasingly of value in understanding the degree to which ALS-FTD may be a 
distinct entity from ALSci, ALS bi (and thus potentially ALScbi). Level III studies are thus 
recommended to include a full staging analysis as delineated by Halliday et al. (135).
Discussion
In contrast to the milieu in which the Strong criteria for the diagnosis of frontotemporal 
dysfunction were crafted, there is now a clearer appreciation of the significant proportion of 
ALS patients who will have evidence of multidimensional dysfunction. When the Strong 
criteria were applied to ALS patients prospectively, more than 50% of ALS patients were 
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found to have some form of frontotemporal disruptions or dementia, including probable 
Alzheimer’ s disease (39,136–139). There is remarkable consistency across virtually all 
studies. The importance of recognising these deficits lies in their impact on survival for a 
large proportion of ALS patients, an impact which is not yet integrated into the design of 
drug trials in ALS. However, executive dysfunction alone is a significant predictor of 
reduced survival from symptom onset (137). Behavioural dysfunction appears also to have 
an equal contribution to survival (p<0.001), seemingly in isolation from other variables 
(140). By increasing the rigor of defining the deficits in ALS, this should be clarified and, 
ultimately, become a defined variable in the design and analysis of clinical trials in ALS.
Advances in our understanding of the spectrum of frontotemporal dysfunction that can occur 
in concert with the motor degeneration of ALS mandated a revision of the Strong criteria. 
Underpinning this is the realisation that there exists a spectrum of deficits which have a 
degree of overlap, and hence the adoption of the term ALS frontotemporal spectrum 
disorders (ALS-FTSD). This is not meant to imply that the spectrum is a continuum, and 
indeed it is less clear that ALS-FTD is the natural endpoint of ALSci, ALSbi or ALS(cbi).
These revised criteria (Table 2) have addressed the issue of genetic testing more critically, in 
part driven by the explosion in knowledge of genetic mutations that are either causally 
associated with ALS, or identified as modifiers of the disease process. The discovery that 
many of these genetic mutations can be observed in ALS patients in whom there is no 
evidence for inheritance underscores the importance of using the term ‘ genetic’  rather than 
‘ familial ALS’  to describe such cases. To that extent, we have proposed that all ALS can be 
stratified into those cases for which a genetic aetiology is known, versus those for which one 
is not. Clearly, there remain cases for which the designation of familial is warranted based 
on a conventional analysis of the patient pedigree; we recommend that these cases also be 
subsumed under the terminology ‘ genetic ALS’ . We are recommending further that all 
patients who are diagnosed as ALS-FTSD be offered the opportunity for genetic testing, and 
in the cases of research protocols, that this be mandatory. While ideally an individual should 
be tested for all genes identified as being causally linked (Table 1), this is impractical and 
beyond the resources of many clinics or individuals. Genetic testing should, therefore, be 
modified according not only to the geography of origin of the patient, but to the nature of the 
deficit (for instance, a patient presenting with marked behavioural impairment, with or 
without psychosis, should first be tested for pathological hexanucleotide expansions of 
C9orf72).
Since the introduction of the Strong criteria, there also has been an increasing awareness that 
the neuropsychological deficits are pervasive across the spectrum of motor neuron diseases. 
The issue arises that even within the motor manifestations of ALS, it is increasingly 
recognised that there is considerable clinical phenotypic heterogeneity. This observation has 
driven controversy as to the degree to which defining this heterogeneity serves any clinical 
purpose, as opposed to considering all disorders of the motor neuron to simply be, on 
aggregate, a single disorder (i.e. lumping vs. splitting). Recent attempts at revising the 
diagnostic criteria for ALS have leaned towards the latter. However, in developing these 
revised Strong criteria, it is hoped that a clearer and more consistent set of criteria by which 
to define the specific variants of frontotemporal dysfunction will provide a clearer 
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understanding of distinct pathophysiology of frontotemporal dysfunction in ALS and, 
potentially, selective treatment responses. While it remains unresolved whether clinically 
divergent presentations are due to disparate aetiologies, it is prudent to maintain careful 
documentation of the clinical phenotype and encourage investigations that may link or 
associate specific presentations with unique biomarkers or aetiologies. The absence of 
maintaining awareness of such clinically divergent motor neuron phenotypes, given our 
current understanding, raises the probability of obscuring a valuable treatment effect or a 
clinical association (perhaps with FTD spectrum) that could highlight a critical aetiology. 
Hence, we have elected to maintain Axis I with a focus on defining the motor neuron disease 
succinctly.
Finally, as with the original Strong criteria, it is recognised that our understanding of the 
frontotemporal dysfunction which may occur in ALS will continue to evolve rapidly. Even 
now, the place of memory and language impairments in ALS are works in progress, as is 
defining the true breadth of behavioural and neuropsychiatric dysfunction which may occur. 
Moreover, recent investigations have begun to elucidate the influence of gender in ALS 
disease manifestation, including ALSci and ALSbi (141). At this point in time, however, it is 
our intention that these revised criteria will provide a greater level of diagnostic certainty.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Schematic of levels of investigation. The revised criteria are designed to address the need for 
rapid, easily applied tools that can be used in the clinical setting (Level I) through to 
assessment tools that are more appropriate to research studies (Level III). Levels II and III 
require formal neuropsychological and speech and language expertise to implement, reflect 
higher statistical complexity, and include tests that may require further validation in the ALS 
population. Level II is an intermediary level which can be applied in clinical trials and would 
be appropriate to be included in clinical case reports as minimum datasets.
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Table 1.
ALS- causative genes and their association with ALS, FTD or ALS-FTSD (adapted from (142,143)).
Clinical Phenotype
Locus Gene ID Chromosome Protein; functional changes Inheritance FTD ALS ALS-
FTSD
other Reference
ALS1 SOD1 21q22.11 Superoxide dismutase 1; Oxidative stress AD, AR + PLS, PMA (144)
ALS2 ALS2 2q33.2 ALSin/Rho guanine nucleotide exchange factors AR + PLS, HSP (145,146)
ALS4 SETX 9q34.13 Senataxin; DNA/RNA processing AD + AOA2 (147)
ALS5 SPG11 15q21.1 Spatacsin; transmembrane protein AR + HSP (148,149)
ALS6 FUS 16p11.2 Fused in Sarcoma; RNA binding protein, DNA repair, exon splicing AD + (#) + + (150–152)
ALS7 Unknown 20p13 Unknown AD + (153)
ALS8 VAPB 20q13.33 Vesicle-associated membrane protein-associated protein B and C; 
Altered axonal transport
AD + SMA (154)
ALS10 TARDBP 1p36.22 TAR DNA binding protein (TDP-43); DNA/RNA processing AD + + + (155–157)
ALS12 OPTN 10p13 Optineurin; membrane and vesicle trafficking, Protein degradation AD, AR + + (PDB) (158)
ALS14 VCP 9q13.3 Valosin-containing protein; ATP-binding protein, vesicle transport and 
fusion
AD + + + MSP (159–161)
ALS15 UBQLN2 X11p.21 Ubiquilin 2; ubiquitination, protein degradation X-linked + + + (162–164)
PFN1 17p13.2 Profilin 1; actin binding protein, actin polymerisation AD + + (165–167)
HnRNPA2B1/A1 7p15.2/12q13.3 Heterogeneous nuclear ribonucleoprotein; mRNA processing AD + MSP (168,169)
ALS-FTD1 Unknown 9q21-q22 Unknown AD + + + (170)
ALS-FTD2 C9orf72 9p21.2 *Chromosome 9 open reading frame 72; unknown AD + + + (171–178)
TBK1 12q154.2 TANK-binding kinase 1; multifunctional kinase active in 
autophagosome-mediated degradation of ubiquitinated proteins; also 
role in inflammatory signalling
AD, sporadic + + (179–184)
AD, autosomal dominant; ALS, amyotrophic lateral sclerosis; AOA2, ataxia-ocular apraxia 2;AR, autosomal recessive; FTD, frontotemporal dementia; HSP, hereditary spastic paraplegia; MSP, multisystem 
proteinopathy (previously referred to as IBMFTD or inclusion body myopathy with Paget’ s disease and frontotemporal dementia); PMA, progressive muscular atrophy; SMA, spinal muscular atrophy; 
TANK, TRAF family member-associated NF-kappa-B activator; TBK1, TANK-binding kinase 1
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Table 2.
Application of Axis I and Axis II diagnostic classification for ALS and ALS-FTSD (modified from Strong et al., 2009) (2).
Heading Subheadings
Existing, 
synonymous terms 
within the literature Characteristics
Axis I. Motor neuron 
disease variant
ALS Sporadic ALS sALS, classic ALS, 
Charcot disease, 
motor neuron disease
A progressive motor system disorder with both UMN and LMN involvement, with the degree of diagnostic certainty further 
defined by either the El Escorial criteria (revised) (6) or the Awaji criteria (9).
genetic ALS gALS; familial ALS 
(fALS)
As indicated for sporadic ALS with the additional components:
1 Confirmed ALS associated genetic mutation, or
2 Clinical evidence of autosomal dominant, autosomal recessive, or X-linked inheritance
Western Pacific 
ALS
Lytico bodig ALS arising within a hyper-endemic region of the western Pacific (e.g., Kii Peninsula, Guam, Rota)
Axis II. 
Neuropsychological 
characterisation
ALSbi A diagnosis of ALSbi requires:
1 The identification of apathy with or without other behaviour change
OR
2 meeting at least two non-overlapping supportive diagnostic features from the Rascovsky criteria (37)
ALSci A diagnosis of ALSci depends on evidence of either executive dysfunction (including social cognition) or language 
dysfunction or a combination of the two.
Executive impairment is defined as:
1 Impaired verbal fluency (letter).
OR
2 Impairment on two other non-overlapping measures of executive functions (which may include social 
cognition)
Language impairment is defined as:
1 Impairment on two non-overlapping tests and in which language impairment is not solely explained by verbal 
fluency deficits.
ALScbi Patients who meet the criteria for both ALSci and ALSbi
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Heading Subheadings
Existing, 
synonymous terms 
within the literature Characteristics
ALS-FTD ALS-dementia (ALS-
D)*, FTD- MND
A diagnosis of ALS-FTD requires:
1 Evidence of progressive deterioration of behaviour and/or cognition by observation or history
AND
2 The presence of at least 3 of the behavioural/cognitive symptoms outlined by Rascovsky, Hodges et al 2011 
(37)
OR
3 The presence of at least 2 of those behavioural/cognitive symptoms, together with loss of insight and/or 
psychotic symptoms
OR
4 The presence of language impairment meeting criteria for semantic dementia/semantic variant PPA or non-
fluent variant PPA. This may co-exist with behavioural/cognitive symptoms as outlined above.
ALS-dementia ALS-D* ALS with dementia, not typical of FTD
ALS-AD ALS in association with Alzheimer’ s disease
ALS-vascular 
dementia
ALS in association with vascular dementia (185)
ALS-mixed 
dementia
ALS in association with a mixed dementia (e.g., AD-vascular dementia)
FTD-MND-like A neuropathological diagnosis in which FTLD is the primary diagnosis but in which there is neuropathological evidence of 
motor neuron degeneration, but insufficient to be classified as ALS
ALS-Parkinsonism-
dementia-complex
Western Pacific 
variant of ALS; lytico 
Bodig
ALS concurrent with dementia and/or Parkinsonism occurring in hyperendemic foci of the western Pacific
*Although less common than in 2009, the term ‘ ALS-dementia’  continues to be used generically within the literature to describe any clinical or neuropathological evidence of neuropsychological 
impairment. Its use does not differentiate between the individual entities and as such appears in more than one category. Its use also is not recommended.
AD, Alzheimer’ s disease; ALS, amyotrophic lateral sclerosis; ALSbi, ALS with behavioural impairment; ALSci, ALS with cognitive impairment; FTLD, frontotemporal lobar degeneration; FTD, 
frontotemporal dementia; LMN, lower motor neuron; PNFA, progressive non-fluent aphasia; SD, semantic dementia; UMN, upper motor neuron
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